← Back to Search

Participants with high-grade glioma for Brain Tumor

Q: What is the current total number of participants being recruited for this clinical study?

Indeed, the information provided on clinicaltrials.gov indicates that this particular clinical trial is actively seeking eligible candidates. The initial posting of the trial occurred on January 5th, 2024, and it was subsequently updated most recently on January 8th, 2024. The study aims to recruit a total of 30 participants across seven different locations.

Q: Are there any available positions for patients to participate in this clinical trial?

Indeed, as per the information available on clinicaltrials.gov, this trial is currently seeking eligible participants. The trial was initially posted on January 5th, 2024 and last updated on January 8th, 2024. A total of 30 patients will be enrolled across seven different sites.

Q: Are there multiple facilities in Canada conducting this clinical trial?

There are a total of 7 active sites participating in this trial, including Memorial Sloan Kettering Monmouth (Consent only) located in Middletown, Memorial Sloan Kettering Suffolk-Commack (Consent only) in Commack, and Memorial Sloan Kettering Basking Ridge (Consent Only) situated in Basking Ridge. Additionally, there are 4 other locations involved in the study.

Phase < 1

Recruiting

Led By Simone Krebs, MD

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Suspicion for or histologically or cytologically confirmed and previously treated HGG or brain metastases from a primary extracranial malignancy

Adults ≥ 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 12 months

Awards & highlights

Study Summary

This trial aims to determine if a type of imaging test called 68Ga-PSMA-11 PET/CT can accurately measure tumor activity in participants with high-grade glioma or brain metastases.

Who is the study for?

This clinical trial is open to individuals with high-grade gliomas or brain metastases. Participants must be suitable for PET/CT scans and have a type of brain tumor that might show activity on these scans.Check my eligibility

What is being tested?

The study is testing the effectiveness of a special imaging scan called 68Ga-PSMA-11 PET/CT in detecting active cancer cells in patients with certain types of aggressive brain tumors or secondary brain cancers.See study design

What are the potential side effects?

As this trial involves diagnostic imaging, side effects may include discomfort at the injection site, allergic reactions to the tracer, and exposure to radiation typical for PET/CT scans.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have or am suspected to have a high-grade glioma or brain metastases from another cancer.

Select...

I am 18 years old or older.

Select...

I can take care of myself but might not be able to do active work.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Assess range of tumor uptake of 68Ga-PSMA-11 in participants

Trial Design

1Treatment groups

Experimental Treatment

Group I: Participants with high-grade gliomaExperimental Treatment1 Intervention

Participants with newly diagnosed or recurrent high-grade glioma/HGG or brain metastases

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor

1,936 Previous Clinical Trials

588,868 Total Patients Enrolled

Simone Krebs, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

1 Previous Clinical Trials

20 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current total number of participants being recruited for this clinical study?

"Indeed, the information provided on clinicaltrials.gov indicates that this particular clinical trial is actively seeking eligible candidates. The initial posting of the trial occurred on January 5th, 2024, and it was subsequently updated most recently on January 8th, 2024. The study aims to recruit a total of 30 participants across seven different locations."

Answered by AI

Are there any available positions for patients to participate in this clinical trial?

"Indeed, as per the information available on clinicaltrials.gov, this trial is currently seeking eligible participants. The trial was initially posted on January 5th, 2024 and last updated on January 8th, 2024. A total of 30 patients will be enrolled across seven different sites."

Answered by AI

Are there multiple facilities in Canada conducting this clinical trial?

"There are a total of 7 active sites participating in this trial, including Memorial Sloan Kettering Monmouth (Consent only) located in Middletown, Memorial Sloan Kettering Suffolk-Commack (Consent only) in Commack, and Memorial Sloan Kettering Basking Ridge (Consent Only) situated in Basking Ridge. Additionally, there are 4 other locations involved in the study."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors

2024. "A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06209567.

All > Brain Tumor